Tag:

BARDA

Latest Headlines

Latest Headlines

Cut loose by BARDA, Biota slashes R&D and hunts for a survival strategy

The news out of Biota Pharmaceuticals has been a steady drumbeat of defeat, setbacks and layoffs for the past two years. And this week the dirge grew even louder with the announcement that the biotech company is slashing the bulk of its staff several weeks after it lost a key government contract to support its work on a new flu drug. 

PPD lands a federal bioterror deal worth up to $100M

PPD has signed a contract with the U.S. government's Biomedical Advanced Research and Development Authority, agreeing to design and conduct clinical trials for products that protect against bioterrorism and other public health emergencies.

Theraclone reels as feds deny funding for flu antibody

Theraclone Sciences was hoping for a federal cash infusion to keep its anti-influenza antibody program rolling, but a denial from the government will force the biotech to handle Phase II on its own.

Cempra wins $58M BARDA contract for lead antibiotic

Chapel Hill, NC-based Cempra has won a $58 million contract from BARDA to develop its lead, late-stage antibiotic for bioterror threats aimed at a pediatric population.

GlaxoSmithKline wins up to $200M federal contract to develop new antibiotics

In the first collaboration of its kind, the U.S. Department of Health and Human Services' Biomedical Advanced Research and Development Authority has brought on GlaxoSmithKline to help the federal agency develop new antibiotics to combat bioterrorism and growing resistance to the drugs.

Achaogen nails $60M in government funding to push antibiotics pipeline

Antibiotics maker Achaogen announced today that it has landed a $60 million contract option from the federal Biomedical Advanced Research and Development Authority to further the development of its drug plazomicin to treat patients with serious Gram-negative bacterial infections.

BioCryst Pharma chops half of staff to cap tumultuous two months

BioCryst Pharmaceuticals ($BCRX) blamed recent setbacks for the company's decision to ax 50% of its workers, according to a release this morning. Its restructuring plans come a week after BioCryst and Presidio Pharmaceuticals jettisoned a $101 million merger agreement that would have brought BioCryst new assets in the sizzling hepatitis C field.

BioCryst scraps $235M late-stage flu drug program backed by feds

After this latest setback, the company's chief medical officer says that it is "unlikely" that the biotech will continue development work needed for U.S. approval.

HHS shoots down bond plan for risky biotech bets

The Biomedical Advanced Research and Development Authority (BARDA), a unit of the U.S. Department of Health and Human Services (HHS), dismissed a biotech industry proposal for using government bonds rather than contracts to fund projects to advance vaccines and other meds for conditions resulting from bioterrorism, Bloomberg reported.

NJ biotech wins $14.5M from U.S. gov't to study drug against anthrax

Uncle Sam has ponied up another $14.5 million in funding to advance Elusys Therapeutics' experimental drug for treating patients after anthrax attacks, according to the company. And the Pine Brook, NJ-based biopharma group is working on a plan for late-stage development of the antibody drug, ETI-204 or Anthim.